West Pharmaceutical Services (WST) Capital Expenditures (2009 - 2026)

West Pharmaceutical Services (WST) has reported Capital Expenditures for 18 consecutive years, with $43.2 million the latest figure, recorded in Q2 2026.

• Quarterly Capital Expenditures fell 42.55% year-over-year to $43.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $225.3 million (down 32.28% YoY) and the FY2025 annual result came in at $285.9 million, down 24.16% from the prior year.
• Capital Expenditures improved to $43.2 million in Q2 2026 per WST's latest filing, from $42.7 million in the prior quarter.
• Over the last five years, Capital Expenditures for WST reached as high as $108.7 million in Q4 2023 and fell as low as $42.7 million in Q1 2026.
• A 5-year average of $77.5 million and a median of $75.8 million in 2023 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures soared 65.74% — and 2026, when it plunged 42.55%.
• Year by year, Capital Expenditures stood at $94.9 million in 2022, then gained by 14.54% to $108.7 million in 2023, then decreased by 3.5% to $104.9 million in 2024, then fell by 27.45% to $76.1 million in 2025, then plunged by 43.23% to $43.2 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $43.2 million, $42.7 million, and $76.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.